Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study assumes that to achieve significant therapeutic efficacy in advanced pancreatic
cancer with immunotherapy, the immune system must remain relatively intact. Therefore, early
use, low tumor load, adequate organ function, and slow growth of the tumor are the key
points. Stage IV pancreatic adenocarcinoma patients with limited metastatic lesions and
adequate organ function will be enrolled. Gemcitabine plus S-1 (GS) will be administered
initially, and then CA 19-9 will be evaluated. Those fulfilling pre-defined criteria of CA
19-9 will receive nivolumab add-on therapy.
Phase:
Phase 2
Details
Lead Sponsor:
National Taiwan University Hospital
Collaborators:
ACT Genomics Ono Pharmaceutical Co. Ltd TTY Biopharm